Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report third-quarter 2024 results on Oct. 31, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $11.3 billion and $1.50 per share, respectively. | --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|-------| | Magnitude Consensus Estimate Trend (60 Days) | Q1 | Q2 | F1 | F2 | | Current | 1.50 | 1.54 | 0.72 | 7.05 | | 7 Days Ago | 1.52 | 1.54 | 0.74 | 7.05 | | ...

Wall Street analysts forecast that Bristol Myers Squibb (BMY) will report quarterly earnings of $1.50 per share in its upcoming release, pointing to a year-over-year decline of 25%. It is anticipated that revenues will amount to $11.3 billion, exhibiting an increase of 3% compared to the year-ago quarter. The current level reflects an upward revision of 0.7% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraise ...

Founder of Dividend Mantra. Founder of Mr. Free At 33. Co-Founder of Dividends & Income. I started blogging about my journey to financial independence back in 2011. By living well below my means and intelligently investing my hard-earned capital, I went from below broke at age 27 to financially free at 33 years old. I regularly create content on dividend growth investing, living off of dividends, undervalued high-quality dividend growth stocks, high-yield situations, and other long-term investment opportuni ...

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today! I initiated coverage of Bristol Myers Squibb Company (NYSE: BMY ) stock in late March 2024 with a "Buy" rating. At the time, I cited that the company's growth potential wasn't exactly what made it worth buying, but Daniel Sereda is chief investment analyst at a fam ...

文章核心观点 - 布里斯托尔-迈尔斯-斯奎布公司(BMY)最近被评为Zacks排名第2(买入),这主要反映了其盈利预测呈上升趋势,这是影响股价的最强大力量之一[1][2][3] - 公司未来盈利能力的变化,如体现在盈利预测修订中,与股价的近期走势有着强烈的相关性,这部分是由于机构投资者使用盈利和盈利预测来计算公司股票的合理价值[3] - Zacks排名股票评级系统有着出色的外部审计业绩记录,Zacks排名第1(强烈买入)的股票自1988年以来平均年收益率为25%[4] 公司层面 - 公司2024财年每股预期收益为0.74美元,同比下降90.2%[5] - 分析师过去3个月一直在上调对公司的盈利预测,Zacks共识预测增加了38.4%[5] - Zacks排名第2(买入)将公司归类为Zacks覆盖股票前20%,表明其盈利预测修订优势,可能在短期内表现良好[6] 行业层面 - Zacks排名股票评级系统在任何市场环境下都保持买入和卖出评级的均衡比例,只有前5%的股票获得"强烈买入"评级,接下来15%的股票获得"买入"评级[6] - 获得Zacks排名前20%的股票表明其盈利预测修订优势,是产生市场超额收益的良好候选[6]

文章核心观点 - 比较了两家医疗生物科技公司Bristol Myers Squibb(BMY)和Vertex Pharmaceuticals(VRTX)的投资价值[1] - 通过分析两家公司的估值指标,认为BMY目前更具价值投资价值[2][3] 公司估值分析 - BMY的市盈率(P/E)为70.56,VRTX的市盈率为7,711.13,BMY的市盈率更低[2] - BMY的市盈率增长(PEG)率为14.11,VRTX的PEG率为582.19,BMY的PEG率更低[2] - BMY的市净率(P/B)为6.19,VRTX的市净率为8.35,BMY的市净率更低[2] 公司基本面分析 - BMY目前的Zacks排名为2(买入),VRTX的排名为3(持有),表明BMY的盈利预测修正更为积极[1]

The most recent trading session ended with Bristol Myers Squibb (BMY) standing at $52.20, reflecting a -0.38% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 0.61%. Elsewhere, the Dow gained 0.97%, while the tech-heavy Nasdaq added 0.33%.The biopharmaceutical company's stock has climbed by 8.62% in the past month, exceeding the Medical sector's loss of 3.79% and the S&P 500's gain of 5.36%.Analysts and investors alike will be keeping a close eye on the performa ...

文章核心观点 - 布里斯托尔-迈尔斯(BMY)获得FDA批准,扩大其重磅免疫肿瘤药物Opdivo(nivolumab)的适应症范围,用于非小细胞肺癌的围手术期治疗[1][2] - Opdivo现已成为唯一一款在该适应症中显示出统计学显著和临床意义上的获益的PD-1抑制剂[2] - BMY还获得FDA批准用于治疗精神分裂症的新药Cobenfy,这是数十年来首个采用新的药理机制的治疗方法[4] - BMY通过收购Mirati Therapeutics和RayzeBio等公司,进一步丰富了其管线,增强了管线实力[8] - 但BMY的债务负担较重,这令人担忧[9] 公司概况 - Opdivo是BMY的关键增长驱动力,2024年上半年销售额达45亿美元[3] - Eliquis、Opdivo和Revlimid是BMY三大主要收入来源,占总收入的61%[7] - Revlimid面临专利到期的挑战,Opdivo也可能面临适应症成熟导致的增长放缓[6][7] - BMY正依靠新药如Opdualag、Reblozyl和Breyanzi来稳定收入基础[5] - BMY通过收购等方式不断丰富管线,如收购Mirati Therapeutics和RayzeBio[8] 财务表现 - BMY股价今年迄今上涨2.3%,优于行业下跌3.9%[10] - 但股价仍低于行业平均水平,估值合理[11] - 未来一年的盈利预测有所上调[12][13] - 但由于并购相关费用的影响,2024年的年度盈利预测大幅下降[13]

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this biopharmaceutical company have returned +6.5% over the past month versus the Zacks S&P 500 composite's +6.4% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has lost 1% over this period. Now the key question is: Where could the stock be headed i ...

文章核心观点 - 公司专注于提供可持续的投资组合收益、多元化和通胀对冲的收益型资产类别 [1] - 公司专注于防御性质的股票,采取中长期投资策略 [1] - 公司分析师拥有14年以上的投资经验,并有金融MBA学位 [1] 行业研究 - 公司分析师拥有10年投资银行从业经验,专注于行业和公司研究 [1] - 公司分析师擅长解读各种新闻、事件、财报等,发现潜在的投资机会和风险 [1] - 公司分析师在撰写文章时表示自己持有相关公司的股票,并表示不会因此获得任何报酬 [2] - 公司分析师提醒读者需要自行进行尽职调查,得出自己的投资决策 [2]